CoviSwift is the world’s first high throughput Point of Care Testing Solution for COVID-19
Mylab Discovery Solutions has announced the approval and launch of CoviSwift – the world’s first point of care high throughput solution for COVID-19. CoviSwift is the first POC testing solution that can be used at small labs, in-hospital labs, airports, villages and allow gold standard testing at high throughputs anywhere. The solution comprises the CoviSwift assay and Compact-Q machines which process 16 samples within 40 minutes. This is approximately four times faster than the traditional method of RT-PCR testing while maintaining the gold standard accuracy.
Mylab has developed software to interpret the results automatically without any expertise in molecular diagnostics. The user just needs to take the nasal sample into tubes, mix and put it into the Compact Q, as simple as a self-test. It will be available in a pack of single tests with all components so that labs do not need to manage reagent storage and logs. CoviSwift comes with a shelf life of 24 months at room temperature – the first in its category – making it a truly made-for -India product.
Technically, CoviSwift is driven by RT-PCR gold standard technology, unlike Rapid PCR methods which are LAMP-based and are currently used at Airport. Rapid PCR / LAMP is usually single gene-based, who’s in-field accuracy is nowhere close to RT-PCR gold standard. This will ensure that now ports of entry have a reliable solution of testing and limit the spread of next variants in the future from other countries or within the country. The test is expected to be available in the market in early February.
